A father has developed a new drug to treat his young son's slow progressing neurodegenerative disorder.
Terry Pirovolakis, 44, received regulatory approval for the clinical treatment this past December - first, in hopes of saving the life of his six-year-old son, Michael, and now to help all affected by the rare disease, .
Spastic paraplegia 50 (SPG50) affects children's development, leading to cognitive impairment, muscle weakness, and paralysis over the course several years. Affecting fewer than 100 worldwide, the disease often ends in death, usually before a patient reaches 30.
Load More
Yorumlar
Kalan Karakter: